Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03026504 · ClinicalTrials.gov registry record · Phase 2
Baricitinib in Relapsing Giant Cell Arteritis
A Phase 2 study of Arteritis, Giant Cell, sponsored by Matthew J Koster.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03026504 is a Phase 2 study of Arteritis, Giant Cell that has completed, run by Matthew J Koster. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03026504, a Phase 2 study of Arteritis, Giant Cell, has completed, sponsored by Matthew J Koster.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and effectiveness of baricitinib in the treatment of giant cell arteritis. All participants will be taking prednisone at the start of the study. The prednisone will be reduced according to a standardized tapering schedule while participants continue to take one tablet of baricitinib daily for 52 weeks.
Conditions Studied
Interventions
- DRUG Baricitinib
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-03-09 |
| Est. Completion | 2021-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03026504
The ClinicalTrials.gov registry entry for NCT03026504 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matthew J Koster, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arteritis, Giant Cell appearing as the primary indexed condition, and to 1 intervention - of which Baricitinib is the first listed.
NCT03026504 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03026504 about?
NCT03026504 is a clinical study titled "Baricitinib in Relapsing Giant Cell Arteritis". This study will evaluate the safety and effectiveness of baricitinib in the treatment of giant cell arteritis. All participants will be taking prednisone at the start of the study. The prednisone will be reduced according to a standardized tapering schedule while participants continue to take one ta...
What is the current status of trial NCT03026504?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2017-03-09. Estimated completion is 2021-04-12.
What conditions does trial NCT03026504 study?
This clinical trial studies the following conditions: Arteritis, Giant Cell.
What interventions are being tested in trial NCT03026504?
The interventions under investigation include: Baricitinib (DRUG).
Who is sponsoring clinical trial NCT03026504?
This trial is sponsored by Matthew J Koster, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03026504 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.